Prescription Trends of Immunosuppressive Drugs in Post-heart Transplant Recipients in Taiwan, 2000-2009

Overview

Journal Pharmacoepidemiol Drug Saf

Publisher Wiley

Specialties Pharmacology
Public Health

Date 2014 Oct 23

PMID 25335855

Citations 3

Authors

Chia-Lin Chou

Chia-Yu Chou

Ying-Yu Huang

Min-Shan Wu

Chia-Chen Hsu

Yueh-Ching Chou

Affiliations

Soon will be listed here.

Abstract

Purpose: Significantly increasing heart transplantations have been performed in Taiwan in the past decades, but the trends of maintenance immunosuppression for heart transplant recipients have not been well known. In this study, we aimed to explore the trends of maintenance immunosuppressive therapy and common complications for heart transplant recipients.

Methods: We retrospectively analyzed ambulatory prescriptions in 488 heart transplant recipients for the period 2000-2009. Patient complications after heart transplantation were also identified.

Results: The annual number of new heart transplant recipients ranged from 18 to 68. The 5-year survival rate was 77.9%. The total number of regimens was 10 in 2000, and increased to 28 in 2009. Most prescriptions were immunosuppressive combinations (95.5%-89.5%). The majority of immunosuppressive regimens were a triple regimen: cyclosporine, mycophenolic acid and corticosteroid in 2009. Cyclosporine was a predominant calcineurin inhibitor with a decreasing trend from 73.9% to 59.1%, whereas the use of tacrolimus significantly increased from 11.9% to 38.4%. Mycophenolic acid was the most frequently used antimetabolite (60.1%-80.3%), while the use of azathioprine was reduced (21.6%-2.3%). From 2008, the launch of everolimus initiated a new era in the utilization of mammalian target of rapamycin inhibitors for maintenance immunosuppression.

Conclusions: Cyclosporine remained the most frequently used calcineurin inhibitors, and tacrolimus increased gradually. Mycophenolic acid was the most popular antimetabolite rather than azathioprine. The rapidly increased everolimus combined regimen may change the patterns of maintenance immunosuppression. The increasing number of combination therapies indicates an active role of everolimus and a tendency of complex tailored individual therapies.

Citing Articles

An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project.

Belleudi V, Rosa A, Finocchietti M, Poggi F, Marino M, Massari M Front Pharmacol. 2022; 13:959267.

PMID: 36188626 PMC: 9521186. DOI: 10.3389/fphar.2022.959267.

Developing a Heart Transplantation Self-Management Support Mobile Health App in Taiwan: Qualitative Study.

Chen Y, Wei J, Chen H, Cheng C, Hou I JMIR Mhealth Uhealth. 2020; 8(8):e18999.

PMID: 32812883 PMC: 7468636. DOI: 10.2196/18999.

Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy.

Lam E, Bashir B, Chaballa M, Kraft W Expert Rev Clin Pharmacol. 2019; 12(8):781-790.

PMID: 31242782 PMC: 6656586. DOI: 10.1080/17512433.2019.1637733.

References

Yagdi T, Sharples L, Tsui S, Large S, Parameshwar J . Malignancy after heart transplantation: analysis of 24-year experience at a single center. J Card Surg. 2009; 24(5):572-9. DOI: 10.1111/j.1540-8191.2009.00858.x. View

Wang S, Chou N, Chi N, Huang S, Wu I, Wang C . Clinical experience of tacrolimus with everolimus in heart transplantation. Transplant Proc. 2012; 44(4):907-9. DOI: 10.1016/j.transproceed.2012.01.094. View

Kobashigawa J . What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Curr Control Trials Cardiovasc Med. 2001; 1(3):166-171. PMC: 59623. DOI: 10.1186/cvm-1-3-166. View

Zuckermann A, Keogh A, Crespo-Leiro M, Mancini D, Gonzalez Vilchez F, Almenar L . Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant. 2012; 12(9):2487-97. DOI: 10.1111/j.1600-6143.2012.04131.x. View

Kobashigawa J, Patel J, Furukawa H, Moriguchi J, Yeatman L, Takemoto S . Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006; 25(4):434-9. DOI: 10.1016/j.healun.2005.11.452. View

Crespo-Leiro M, Alonso-Pulpon L, Vazquez de Prada J, Almenar L, Arizon J, Brossa V . Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant. 2008; 8(5):1031-9. DOI: 10.1111/j.1600-6143.2008.02196.x. View

Eisen H, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R . Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005; 24(5):517-25. DOI: 10.1016/j.healun.2005.02.002. View

Chen P, Chang H, Chen I, Lai S, Shih C, Weng Z . Malignancy after heart transplantation. J Chin Med Assoc. 2009; 72(11):588-93. DOI: 10.1016/S1726-4901(09)70434-4. View

Lund L, Edwards L, Kucheryavaya A, Dipchand A, Benden C, Christie J . The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. J Heart Lung Transplant. 2013; 32(10):951-64. DOI: 10.1016/j.healun.2013.08.006. View

10.

Kobashigawa J, Miller L, Russell S, Ewald G, Zucker M, Goldberg L . Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006; 6(6):1377-86. DOI: 10.1111/j.1600-6143.2006.01290.x. View

11.

Gullestad L, Iversen M, Mortensen S, Eiskjaer H, Riise G, Mared L . Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89(7):864-72. DOI: 10.1097/TP.0b013e3181cbac2d. View

12.

Lehmkuhl H, Mai D, Dandel M, Knosalla C, Hiemann N, Grauhan O . Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant. 2007; 26(7):700-4. DOI: 10.1016/j.healun.2007.02.008. View

13.

Kobashigawa J, Tobis J, Mentzer R, Valantine H, Bourge R, Mehra M . Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006; 6(5 Pt 1):993-7. DOI: 10.1111/j.1600-6143.2006.01297.x. View

14.

Fraund S, Pethig K, Franke U, Wahlers T, Harringer W, Cremer J . Ten year survival after heart transplantation: palliative procedure or successful long term treatment?. Heart. 1999; 82(1):47-51. PMC: 1729113. DOI: 10.1136/hrt.82.1.47. View

15.

ONeill J, Edwards L, Taylor D . Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25(10):1186-91. DOI: 10.1016/j.healun.2006.06.010. View

16.

Segovia J, Gomez-Bueno M, Alonso-Pulpon L . Treatment of allograft vasculopathy in heart transplantation. Expert Opin Pharmacother. 2006; 7(17):2369-83. DOI: 10.1517/14656566.7.17.2369. View

17.

Mastrobuoni S, DellAquila A, Azcarate P, Rabago G, Herreros J . Long-term survival (>20 years) following heart transplantation. J Cardiovasc Surg (Torino). 2012; 53(5):677-84. View

18.

Stehlik J, Edwards L, Kucheryavaya A, Benden C, Christie J, Dipchand A . The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. J Heart Lung Transplant. 2012; 31(10):1052-64. DOI: 10.1016/j.healun.2012.08.002. View

19.

Dantal J, Soulillou J . Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005; 352(13):1371-3. DOI: 10.1056/NEJMe058018. View

20.

Aleksic I, Baryalei M, Busch T, Pieske B, Schorn B, Strauch J . Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation. 2000; 69(8):1586-90. DOI: 10.1097/00007890-200004270-00012. View